AbbVie Inc (ABBV)vsOwlet Inc (OWLT)
ABBV
AbbVie Inc
$202.71
-1.13%
HEALTHCARE · Cap: $365.43B
OWLT
Owlet Inc
$4.86
-6.54%
HEALTHCARE · Cap: $142.34M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 59327% more annual revenue ($62.82B vs $105.71M). ABBV leads profitability with a 5.8% profit margin vs -37.5%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
OWLT
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-20.5%
Fair Value
$168.19
Current Price
$202.71
$34.52 premium
Margin of Safety
+30.6%
Fair Value
$15.80
Current Price
$4.86
$10.94 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 31.6%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 4.9B in free cash flow
Revenue surging 29.6% year-over-year
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 45.8%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -802.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.
Bull Case : OWLT
The strongest argument for OWLT centers on Revenue Growth. Revenue growth of 29.6% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.8x leaves little room for execution misses.
Bear Case : OWLT
The primary concerns for OWLT are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while OWLT is a growth play — different risk/reward profiles.
OWLT carries more volatility with a beta of 1.83 — expect wider price swings.
OWLT is growing revenue faster at 29.6% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 32/100) and 12.4% revenue growth. OWLT offers better value entry with a 30.6% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Owlet Inc
HEALTHCARE · MEDICAL DEVICES · USA
Owlet Inc. is a leading innovator in infant health technology, focused on enhancing the safety and well-being of newborns through state-of-the-art monitoring solutions. The company's flagship product, the Owlet Smart Sock, employs advanced pulse oximetry to deliver real-time data on infants' heart rates and oxygen levels directly to parents’ mobile devices, empowering them with critical health insights. As the demand for pediatric health monitoring grows, Owlet is strategically positioned to broaden its product portfolio and solidify its standing in the dynamic infant health market. By emphasizing actionable data and improving pediatric care, Owlet is establishing a robust foothold at the intersection of healthcare and technology, appealing to institutional investors keen on innovative health solutions.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?